検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1521 : JHOS-2  update : 2021/02/26
細胞特性(Comment:英)Human cell line derived from ovarian serous adenocarcinoma. Said CA125 and CA15-3 producing. Application consideration
細胞特性(日)ヒト卵巣癌由来細胞株。Serous adenocarcinoma. CA125, CA15-3産生性という。培養開始にあたっての注意
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)A prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
使用条件(日)営利目的か非営利目的かを問わず、いかなる使用につきましても、承諾者(寄託者)から承諾を得ることが必要です。
備考(英)
備考(日)
承諾者住所
×
Japanese
住所
問い合わせ先
cellbank.brc@riken.jp
理化学研究所   細胞材料開発室
提供 係 先生
Fax. 029-836-9130

English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank
Fax. +81-29-836-9130
提供申込書類(英) Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   承諾書C-0002.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず(cellbank.brc@riken.jp)までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Ishikawa, Hiroshi
樹立者 Ishikawa, H. & Yasuda, M.
寄託日 1999
動物種 _human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Female
45 years
採取組織 ovary
病名 serous adenocarcinoma of ovary
転移 Yes
転移巣 lymph node
細胞分類 cancer
初代培養日 1997
細胞寿命 infinite
細胞形態 epithelial-like
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 DMEM/HamF12 + 10% FBS + 0.1mM NEAA
抗生物質 Free
継代方法 (0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : once/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
個体識別検査 OK
アイソザイム検査 LD, NP
染色体検査 74-83(50) : /76(7),77(6),78(8),79(9),80(4),81(5)/
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 1件
Reference(日) 0件
利用者成果(英) 16件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
2405  Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H  Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary.  Hum Cell  1999  12:131-8  PubMed ID: 10695020

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
13066  Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D.  Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.  Mol Cell  2020    PubMed ID: 32516598
13262  Escalona RM, Bilandzic M, Western P, Kadife E, Kannourakis G, Findlay JK, Ahmed N.  TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.  BMC Cancer  2020    PubMed ID: 33023532
13385  Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Yang A, Kalekar RL, Krill-Burger JM, Dharia NV, Kugener G, Kalfon J, Yuan C, Dumont N, Gonzalez A, Abdusamad M, Li YY, Spurr LF, Wu WW, Durbin AD, Wolpin BM, Piccioni F, Root DE, Boehm JS, Cherniack AD, Tsherniak A, Hong AL, Hahn WC, Stegmaier K, Golub TR, Vazquez F, Aguirre AJ.  Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.  Cell Rep  2020    PubMed ID: 33326793
13387  Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T.  Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.  Biomolecules  2020    PubMed ID: 33339442
13700  Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N.  Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer  FEBS Lett  2020  594(9):1379-1388  PubMed ID: 31950503
11501  Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.  Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.  Biochem. Biophys. Res. Commun.  2019    PubMed ID: 30955858
11511  Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.  Nature  2019    PubMed ID: 30971826
13420  Hamedi, Bahareh  Anti-cancer effects of n-3 long-chain polyunsaturated fatty acids (LCPUFA) on ovarian cancer growth in vitro and in vivo    2019   
10833  Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N.  Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.  Nat Commun  2018  9:1685  PubMed ID: 29703902
10676  Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.  A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.  Sci Rep  2017  7:18086  PubMed ID: 29273809
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935
9658  Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii  Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423  PLoS One  2014  9(2):e87220  PubMed ID: 24504419
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532
2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672
3094  Kaneda, Atsushi, Wakazono, Kuniko, Tsukamoto, Tetsuya, Watanabe, Naoko, Yagi, Yukiko, Tatematsu, Masae, Kaminishi, Michio, Sugimura, Takashi, Ushijima, Toshikazu  Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.  Cancer Res  2004  64:6410-5  PubMed ID: 15374948
3796  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ